Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 2016, Issue , 2016, Pages

  Zhanel, George G ^a   Walkty, Andrew J ^a   Karlowsky, James A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; BETA LACTAM; BILIRUBIN; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN TROMETAMOL; HEMOGLOBIN; METOCLOPRAMIDE; NITROFURANTOIN;

ABDOMINAL PAIN; ACUTE UNCOMPLICATED CYSTITIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ASTHENIA; ASTHMA; BACKACHE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CYSTITIS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; EOSINOPHIL COUNT; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FATIGUE; GLOMERULUS FILTRATION; HEMATOCRIT; HUMAN; IN VITRO STUDY; KIDNEY CONCENTRATING CAPACITY; LIVER NECROSIS; MAXIMUM PLASMA CONCENTRATION; MIC50; MIC90; NAUSEA; NONHUMAN; OBSTRUCTIVE JAUNDICE; PREGNANCY; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC MEGACOLON; VAGINITIS; VOLUME OF DISTRIBUTION;

EID: 84971635920     PISSN: 17129532     EISSN: 19181493     Source Type: Journal    
DOI: 10.1155/2016/2082693     Document Type: Review

References (62)

1. A. Sultan,M. Rizvi, F. Khan,H. Sami, I. Shukla, and H. M. Khan, "Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer?" Urology Annals, vol. 7, no. 1, pp. 26-30, 2015.
2. M. A. Pezzlo, "Laboratory diagnosis of urinary tract infections: guidelines, challenges, and innovations," Clinical Microbiology Newsletter, vol. 36, no. 12, pp. 87-93, 2014.
3. S. A. Mehnert-Kay, "Diagnosis and management of uncomplicated urinary tract infections," American Family Physician, vol. 72, no. 3, pp. 451-458, 2005.
4. A. Wang, P. Nizran, M. A. Malone, and T. Riley, "Urinary tract infections," Primary Care: Clinics in Office Practice, vol. 40, no. 3, pp. 687-706, 2013.
5. L. Nicolle, P. A. M. Anderson, J. Conly et al., "Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment," Canadian Family Physician, vol. 52, pp. 612-618, 2006.
6. K. Gupta, T. M. Hooton, K. G. Naber et al., "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases," Clinical Infectious Diseases, vol. 52, no. 5, pp. e103-e120, 2011.
7. J. A. Karlowsky, P. R. S. Lagacé-Wiens, P. J. Simner et al., "Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study," Antimicrobial Agents and Chemotherapy, vol. 55, no. 7, pp. 3169-3175, 2011.
8. A. Sorlozano, A. Jimenez-Pacheco, J. de Dios Luna del Castillo et al., "Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: A 7-year surveillance study," American Journal of Infection Control, vol. 42, no. 10, pp. 1033-1038, 2014.
9. J. A. Karlowsky, A. J. Denisuik, P. R. S. Lagacé-Wiens et al., "In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study," Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 1252-1256, 2014.
10. B. G. Christensen,W. J. Leanza, T. R. Beattie et al., "Phosphonomycin: structure and synthesis," Science, vol. 166, pp. 123-125, 1969.
11. G. G. Grassi, "Fosfomycin trometamol: historical background and clinical development," Infection, vol. 18, supplement 2, pp. S57-S59, 1990.
12. M. Popovic, D. Steinort, S. Pillai, and C. Joukhadar, "Fosfomycin: An old, new friend?" European Journal of Clinical Microbiology and Infectious Diseases, vol. 29, no. 2, pp. 127-142, 2010.
13. P. J. Bergen,C. B. Landersdorfer,H. J. Lee, J. Li, and R. L. Nation, "'Old' antibiotics for emerging multidrug-resistant bacteria," Current Opinion in Infectious Diseases, vol. 25, no. 6, pp. 626-633, 2012.
14. Monurol Fosfomycin Trometamol Product Monograph, Springer Healthcare Italia Srl, Milano, Italia, 2012.
15. R. D. Woodyer, Z. Shao, P. M. Thomas et al., "Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster," Chemistry and Biology, vol. 13, no. 11, pp. 1171-1182, 2006.
16. F. M. Kahan, J. S. Kahan, P. J. Cassidy, and H. Kropp, "The mechanismof actionof fosfomycin (phosphonomycin)," Annals of theNew York Academy of Sciences, vol. 235, pp. 364-386, 1974.
17. J. M. Andrews, F. Baquero, J. M. Beltran et al., "International collaborative study on standardization of bacterial sensitivity to fosfomycin," Journal of Antimicrobial Chemotherapy, vol. 12, no. 4, pp. 357-361, 1983.
18. Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement," Tech. Rep. M100-S25, 2015.
19. P.-L. Ho, J. Chan, W.-U. Lo et al., "Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates," Journal of Medical Microbiology, vol. 62, no. 11, pp. 1707-1713, 2013.
20. J. Navas, J. León, M. Arroyo, and J. M. García Lobo, "Nucleotide sequence and intracellular location of the product of the fosfomycin resistance gene from transposon Tn2921," Antimicrobial Agents and Chemotherapy, vol. 34, no. 10, pp. 2016-2018, 1990.
21. R. E. Rigsby, K. L. Fillgrove, L. A. Beihoffer, and R. N. Armstrong, "Fosfomycin resistance proteins: A nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily," Methods in Enzymology, vol. 401, pp. 367-379, 2005.
22. M. Ballestero-Tellez, F. Docobo-Perez, J. M. Rodriguez-Martinez et al., "Contribution of specific resistance mechanisms of fosfomycin resistance and its biological cost in Escherichia coli," in Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '15), September 2015.
23. D. E. Karageorgopoulos, R. Wang, X.-H. Yu, and M. E. Falagas, "Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens," Journal of Antimicrobial Chemotherapy, vol. 67, no. 2, Article ID dkr466, pp. 255-268, 2012.
24. S. V. Sharma, V. K. Jothivasan, G. L. Newton et al., "Chemical and chemoenzymatic syntheses of bacillithiol: A unique lowmolecular-weight thiol amongst low G + C gram-positive bacteria," Angewandte Chemie-International Edition, vol. 50, no. 31, pp. 7101-7104, 2011.
25. A. A. Roberts, S. V. Sharma, A. W. Strankman, S. R. Duran, M. Rawat, and C. J. Hamilton, "Mechanistic studies of FosB: A divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in Staphylococcus aureus," Biochemical Journal, vol. 451, no. 1, pp. 69-79, 2013.
26. P. García, P. Arca, and J. EvaristoSuárez, "Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate," Antimicrobial Agents and Chemotherapy, vol. 39, no. 7, pp. 1569-1573, 1995.
27. F. Gudiol, "S55 Facts and myths about fosfomycin," International Journal of Antimicrobial Agents, vol. 29, supplement 2, pp. S12-S13, 2007.
28. J. Oteo, V. Bautista, N. Lara et al., "Parellel increase in community use of fosfomycin and resistance to fosfomycin in extendedspectrumbeta-lactamase-producing Escherichia coli," Journal of Antimicrobial Chemotherapy, vol. 65, pp. 2459-2463, 2010.
29. J. Oteo, V. Bautista, N. Lara et al., "Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum-lactamase (ESBL)-producing Escherichia coli," Journal of Antimicrobial Chemotherapy, vol. 65, no. 11, Article ID dkq346, pp. 2459-2463, 2010.
30. A. Marchese, L. Gualco, E. A. Debbia, G. C. Schito, and A. M. Schito, "In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance," International Journal of Antimicrobial Agents, vol. 22, no. 2, pp. S53-S59, 2003.
31. G. C. Schito, K. G. Naber, H. Botto et al., "The ARESC study: An international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections," International Journal of Antimicrobial Agents, vol. 34, no. 5, pp. 407-413, 2009.
32. European Committee on Antimicrobial Susceptibility Testing Clinical breakpoints-bacteria, version 5. 0. 2015.
33. A. L. Barry and P. C. Fuchs, "In vitro susceptibility testing procedures for fosfomycin tromethamine," Antimicrobial Agents and Chemotherapy, vol. 35, no. 6, pp. 1235-1238, 1991.
34. A. L. Barry and S. D. Brown, "Antibacterial spectrum of fosfomycin trometamol," Journal of Antimicrobial Chemotherapy, vol. 35, no. 1, pp. 228-230, 1995.
35. L. V. Perdigao-Neto, M. S. Oliveira, C. F. Rizek, C. M. D. M. Carrilho, S. F. Costa, and A. S. Levin, "Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testingmethods," AntimicrobialAgents and Chemotherapy, vol. 58, no. 3, pp. 1763-1767, 2014.
36. A. Alhambra, J. A. Cuadros, J. Cacho, J. L. Gómez-Garcés, and J. I. Alós, "In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics," Journal of Antimicrobial Chemotherapy, vol. 53,no. 6, pp. 1090-1094, 2004.
37. S. Rajenderan, V. Balaji, S. Anandan et al., "Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: A prospective study," PLoS ONE, vol. 9, article 7, Article ID e103253, 2014.
38. H. Hayami, S. Takahashi, K. Ishikawa et al., "Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: Antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus," Journal of Infection and Chemotherapy, vol. 19, no. 3, pp. 393-403, 2013.
39. K. S. Ko, J. Y. Suh, K. R. Peck et al., "In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum -lactamase-producing Escherichia coli isolated fromurine and blood," Diagnostic Microbiology and Infectious Disease, vol. 58, no. 1, pp. 111-115, 2007.
40. M. Kresken, Y. Pfeifer, D. Hafner, R. Wresch, and B. Körber-Irrgang, "Occurrence ofmultidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum -lactamases and the role of fosfomycin," International Journal of Antimicrobial Agents, vol. 44, no. 4, pp. 295-300, 2014.
41. M.-S. Hsu, C.-H. Liao, C.-Y. Liu, C.-J. Yang, Y.-T. Huang, and P.-R. Hsueh, "In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents," International Journal of Antimicrobial Agents, vol. 37, no. 3, pp. 276-278, 2011.
42. M. B. Perri, E. Hershberger,M. Ionescu, C. Lauter, and M. J. Zervos, "In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin," Diagnostic Microbiology and Infectious Disease, vol. 42, no. 4, pp. 269-271, 2002.
43. M. E. Falagas, K. P. Giannopoulou, G. N. Kokolakis, and P. I. Rafailidis, "Fosfomycin: use beyond urinary tract and gastrointestinal infections," Clinical Infectious Diseases, vol. 46,no. 7, pp. 1069-1077, 2008.
44. A. Endimiani, G. Patel, K. M. Hujer et al., "In vitro activity of fosfomycin against KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and /or colistin," Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, pp. 526-529, 2010.
45. M. Kaase, F. Szabados, A. Anders, and S. G. Gatermann, "Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany," Journal of Clinical Microbiology, vol. 52, no. 6, pp. 1893-1897, 2014.
46. M. E. Falagas,S. Maraki,D. E. Karageorgopoulos, A. C. Kastoris, E. Mavromanolakis, and G. Samonis, "Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drugresistant (XDR) Enterobacteriaceae isolates to fosfomycin," International Journal of Antimicrobial Agents, vol. 35, no. 3, pp. 240-243, 2010.
47. A. S. Michalopoulos, I. G. Livaditis, and V. Gougoutas, "The revival of fosfomycin," International Journal of Infectious Diseases, vol. 15, no. 11, pp. e732-e739, 2011.
48. S. S. Patel, J. A. Balfour, and H. M. Bryson, "Fosfomycin Tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections," Drugs, vol. 53, no. 4, pp. 637-656, 1997.
49. G. M. Keating, "Fosfomycin trometamol: A review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria," Drugs, vol. 73, no. 17, pp. 1951-1966, 2013.
50. N. Roussos, D. E. Karageorgopoulos, G. Samonis, and M. E. Falagas, "Clinical significance of the pharmacokinetic and pharmacodynamics characteristics of fosfomycin for the treatment of patients with systemic infections," International Journal of Antimicrobial Agents, vol. 34, pp. 506-515, 2009.
51. W. M. M. Kirby, "Pharmacokinetics of fosfomycin," Chemotherapy, vol. 23, pp. 141-151, 1977.
52. M. E. Falagas and P. I. Rafailidis, "Fosfomycin: the current status of the drug," Clinical Infectious Diseases, vol. 61, no. 7, pp. 1144-1146, 2015.
53. T. Mazzei,M. I. Cassetta, S. Fallani, S. Arrigucci, and A. Novelli, "Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections," International Journal of Antimicrobial Agents, vol. 28, supplement 1, pp. 35-41, 2006.
54. F. Docobo-Pérez, G. L. Drusano, A. Johnson et al., "Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance,"AntimicrobialAgents and Chemotherapy, vol. 59, no. 9, pp. 5602-5610, 2015.
55. N. Ceran,D. Mert, F. Y. Kocdogan et al., "Arandomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections," Journal of Infection and Chemotherapy, vol. 16, no. 6, pp. 424-430, 2010.
56. J. L. Reffert and W. J. Smith, "Fosfomycin for the treatment of resistant gram-negative bacterial infections," Pharmacotherapy, vol. 34, no. 8, pp. 845-857, 2014.
57. G. V. Sanchez, R. N. Master, J. A. Karlowsky, and J. M. Bordon, "In vitro antimicrobial resistance of urinary Escherichia coli isolates among U. S. outpatients from 2000 to 2010," Antimicrobial Agents and Chemotherapy, vol. 56, no. 4, pp. 2181-2183, 2012.
58. A. Walkty, P. R. S. Lagacé-Wiens, J. A. Karlowsky et al., "Change in antimicrobial susceptibility of escherichia coli urinary tract isolates at a single institution over a period of 10 years," Canadian Journal of Microbiology, vol. 58, no. 3, pp. 345-349, 2012.
59. Y. Doi, Y. S. Park, J. I. Rivera et al., "Community-associated extended-spectrum -lactamase-producing Escherichia coli infection in the United States," Clinical Infectious Diseases, vol. 56, no. 5, pp. 641-648, 2013.
60. L. Grigoryan, B. W. Trautner, and K. Gupta, "Diagnosis and management of urinary tract infections in the outpatient setting: A review," The Journal of the AmericanMedical Association, vol. 312, no. 16, pp. 1677-1684, 2014.
61. M. Grabe, R. Bartoletti, T. E. Bjerklund Johansen et al., Guidelines on Urological Infections, European Association of Urology, 2015.
62. Anti-Infective Review Panel, Anti-Infective Guidelines for Community Acquired Infections, Anti-Infective Review Panel, 2014.